TNF and pneumonia: Thus, anti-TNFα antibodies, and adalimumab in particular thanks to its excellent safety profile [74], could inhibit the basic mechanisms of COVID-19, and could be potentially useful in managing/preventing COVID-19-driven pneumonia[75].